Outset Medical’s Q2 2026: Margin Gains, HCA Refresh Bet, and the Quiet EPS Watch

Quarterly snapshot

Net revenue totaled $31.6 million, up 1% from the second quarter of 2025 and up 14% sequentially. Recurring revenue—primarily Tablo consumables and services—stood at $22.1 million and was roughly flat versus the prior year. The company disclosed a gross margin of 42.0%, an improvement of more than 400 basis points versus the year-ago period; non-GAAP gross margin registered at 42.2%.

Product revenue amounted to $21.9 million and declined about 5% year over year, while service and other revenue was $9.7 million, up ~17% versus the prior-year period.

Margin dynamics and product mix

The mix shift toward services and a stronger gross margin signal a more favorable unit economics trajectory, even as product revenue softens year over year. Gross profit rose to $13.3 million, a 12% year-over-year improvement, with product gross profit at $10.1 million and a product gross margin of 46.1%. Service and other gross profit came in at $3.2 million, with a gross margin of 32.6%.

Strategic moves and operational highlights

Management highlighted ongoing progress across the business, noting the strongest cadence of new site installations in several years and the completion of a meaningful backlog-visible milestone via a refreshed revenue opportunity. A notable development was a three-year, $40 million agreement with HCA Healthcare to refresh the fleet of Tablo systems across the United States’ largest health system—a signal that a meaningful expansion in installed-base capacity and service revenue could be on deck.

“Second quarter results reflect continued progress in strengthening the foundation of our business while positioning Outset for the next phase of growth,” said Leslie Trigg, Chair and Chief Executive Officer. “During the quarter, we completed our highest number of successful new site installations in several years. We also signed our first refresh agreement, which enhances backlog visibility and marks an important milestone as we begin to capitalize on a significant refresh opportunity.”

Financial results and cost structure

Second-quarter 2026 revenue figures tie into a broader picture: operating expenses were recorded at $29.0 million, with research and development (R&D) running at $5.5 million and selling & marketing (S&M) expenses at $12.2 million. The quarterly cash burn amounted to $9.5 million, contributing to a cash, cash equivalents, short-term investments and restricted cash balance of $151 million at quarter end.

What this means for OM and peers in the space

The Q2 results present a narrative of improving gross margins and a cautious but real step-change in revenue quality through a rising contribution from services and a substantial refresh program. The HCA deal anchors a potential multi-year stream of service and installation activity, helping to stabilize backlog visibility and potentially cushion volatility in standalone device sales.

From a competitive vantage point, Outset seems to be leaning into the installed-base refresh cycle as a lever for revenue predictability. For sector peers, the emphasis on consumables and service revenue could become a more salient driver of gross margin improvement should installation volumes accelerate and renewal cycles extend beyond a single quarter. Investors will watch whether this margin expansion can translate into sustainable profitability, a key question given the current operating-expense footprint.

EPS, earnings expectations, and revenue commentary

One notable point for readers tracking EPS and EPS consensus is that the release does not provide an earnings-per-share figure or a formal EPS consensus target. Nor is there a published explicit revenue forecast for the second half of 2026. In earnings-reporting practice, that means analysts will interpret the topline growth, margin trajectory, and the HCA refresh milestone alongside guidance or cadence in subsequent updates. In other words, the market will continue to infer profitability path and potential earnings surprises from the rhythm of gross margin gains and cash burn—not from a headline EPS beat or miss at present.

Outlook and what’s next

Absent a formal revenue forecast or EPS guidance in this release, investors will set their own pace for judging trajectory—focusing on the sustainability of the 42% gross margin, the scale and timing of Tablo-related service revenue, and the pace of new-site installations and backlog conversion. The HCA refresh deal is a meaningful data point; if the relationship scales, OM could transform a portion of its revenue into a steadier, recurring stream, potentially altering the earnings cadence over the next several quarters.

Bottom line

Outset Medical’s Q2 2026 report emphasizes margin resilience and a growth narrative anchored by a high-visibility refresh program with HCA Healthcare. While the absence of an EPS figure and revenue forecast leaves some questions about the near-term earnings trajectory, the combination of a solid top-line pace, a pivot toward services, and a meaningful backlog anchor suggests the company is laying groundwork for durable cash generation and improved profitability—not in a single-quarter flash, but as a multi-quarter arc. For OM and its peers, the takeaway is clear: the next few quarters will test whether the service-heavy model can translate into meaningful, earnings-quality profitability as the installed base expands.